europabio-logoeuropabio-logoeuropabio-logoeuropabio-logo
  • About us
    • Who we are
      • Governance
      • Staff
      • Vacancies
    • What we do
  • Members
    • EuropaBio Members
    • About Membership
  • How we work
    • Healthcare Biotechnology Council
      • Cell & Gene Therapies
      • Medicines For Rare Diseases And Children
      • Regulatory Efficiency
      • Biosimilars & Public Procurement
      • Data & Digital
      • Patient Bio-Forum
    • Industrial Biotechnology Council
      • Food, Feed & Nutrition
      • Circular Bioeconomy
    • National Associations Council
    • SME Platform
    • Biomanufacturing Platform
  • Activities
    • 25 Years of Innovation
    • EFIB 2022
    • European Biotech Week
  • Events
  • Newsroom
    • News & Publications
    • Library
Become a member
✕

EuropaBio presents EFIB Vilnius Statement to European policymakers

30/11/2022
PRESS RELEASE

Today,  EuropaBio hosted the official launch event of the EuropaBio's EFIB Vilnius Statement of 2022, with a round table dedicated to discussion around the role and potential of enabling technologies in the EU green transition. Policy makers, Member States and other stakeholders joined EuropaBio members to drive the discussion. 

The launch reflects the official Statement generated from EuropaBio’s 15th European Forum for Industrial Biotechnology & the Bioeconomy (EFIB) ‘’Next generation economies: industrial biotechnology for a sustainable society’ in Vilnius, Lithuania. 350 delegates from 18 countries worldwide and across multiple sectors gathered to address the economic future for industrial biotechnology, resulting in the Vilnius Statement formally launched in Brussels today.

‘’Today, we are honoured to present the EFIB Vilnius statement to European policymakers, coming at a critical time of current global challenges such as Covid recovery, food supply chain and energy security. Delivering on EU Green Deal objectives whilst strengthening resilience and independence of European industries is essential and industrial biotechnology and biomanufacturing are part of the solution’’, said Dr Claire Skentelbery, Director General of EuropaBio.

The EFIB Vilnius statement set the stage with three industry asks for 2023 and beyond:

  1. Modernalizing regulation and policy: enabling impact

For a cohesive approach across sectors, advanced knowledge on microorganisms should be recognised and considered when developing the policy action for plants developed using NGTs.

 

  1. Education and awareness: enabling citizens

For maximum economic return from advanced technologies, supporting skills should be a priority throughout Europe, integral to all industrial and innovation development.

 

  1. Financing innovation: enabling technologies

The power of industrial biotechnology as an enabling technology should be recognised within financial frameworks to allow a substantial contribution in key economic sectors.

 

The official Vilnius statement presentation was followed by a handover of the document to the European Commission which was presented by Simonas Šatūnas, Head of Cabinet of the Virginijus Sinkevičius, Commissioner for Environment. S. Šatūnas in his follow up remark highlighted the importance to emphasise economic side of the circular economy narrative rather than focusing solely on biodiversity or reduction of the pollution.

The roundtable continued with interventions from IFF, Novozymes, BioPharmaChem Ireland, European Commission representatives and attaches from various national Permanent Representations to the European Union. Discussions revealed a common goal to make Europe a leader in biomanufacturing, reinforce skills and talent development and favourable regulatory environment.

At the end of the meeting, Claire Skentelbery invited participants to continue a discussion on this topic and evaluate the implementation of the Vilnius statement next year, during the next edition of EFIB which will take place in October 24-25, 2023 in Rotterdam, the Netherlands.

EuropaBio presents EFIB Vilnius Statement to European policymakers


Download

Share
Alexandra Simionca
Alexandra Simionca

Related posts

17/01/2023

EuropaBio launches SME BioForum in Rare Diseases


Read more
17/01/2023

EuropaBio launches Industry Advisory Group for new Biomanufacturing Platform


Read more
16/01/2023

SwiftPharma joins EuropaBio: pioneering sustainable, scalable and affordable plant-made therapeutic proteins


Read more
19/12/2022

EuropaBio sat down with new member Association of Biotechnological Companies Bioforum, to find out how they champion biotech in central and eastern Europe


Read more

Important links

  • EuropaBio launches SME BioForum in Rare Diseases
  • EuropaBio launches Industry Advisory Group for new Biomanufacturing Platform

Categories in our Newsroom

Search by tags

  • Innovation
  • Excellence
  • Science
  • ATMPs
  • Healthcare Biotech
  • Industrial Biotech
  • Investment
  • EuropaBio
  • EFIB
  • Regulation
  • Rare Diseases
  • COVID-19
  • Members
  • Cancer
  • Patients
  • Patient BioForum
  • Gene & Cell Therapies
  • Accessibility
  • Intellectual Property
  • Pharmaceutical Strategy for Europe

Subscribe for our newsletter

Subscribe to the EuropaBio newsletter to receive the latest news and developments in the Biotech sector!


Subscribe
EuropaBio-Logo-White

EuropaBio represents corporate and associate members across sectors, plus national and regional biotechnology associations which, in turn, represent over 2600 biotech companies, 2300 out of them are SMEs.

Contact us

Extra links

Members
Staff
Privacy policy
Legal & cookies
Events
Newsroom

Become a member

Media pack

© 2023 Europabio. All Rights Reserved. Designed by EYAS
Become a member